Age-linked suppression of lipoxin A4 associates with cognitive deficits in mice and humans

Transl Psychiatry. 2022 Oct 10;12(1):439. doi: 10.1038/s41398-022-02208-1.

Abstract

Age increases the risk for cognitive impairment and is the single major risk factor for Alzheimer's disease (AD), the most prevalent form of dementia in the elderly. The pathophysiological processes triggered by aging that render the brain vulnerable to dementia involve, at least in part, changes in inflammatory mediators. Here we show that lipoxin A4 (LXA4), a lipid mediator of inflammation resolution known to stimulate endocannabinoid signaling in the brain, is reduced in the aging central nervous system. We demonstrate that genetic suppression of 5-lipoxygenase (5-LOX), the enzyme mediating LXA4 synthesis, promotes learning impairment in mice. Conversely, administration of exogenous LXA4 attenuated cytokine production and memory loss induced by inflammation in mice. We further show that cerebrospinal fluid LXA4 is reduced in patients with dementia and positively associated with cognitive performance, brain-derived neurotrophic factor (BDNF), and AD-linked amyloid-β. Our findings suggest that reduced LXA4 levels may lead to vulnerability to age-related cognitive disorders and that promoting LXA4 signaling may comprise an effective strategy to prevent early cognitive decline in AD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Alzheimer Disease* / genetics
  • Animals
  • Arachidonate 5-Lipoxygenase / genetics
  • Brain-Derived Neurotrophic Factor
  • Cognition
  • Cognitive Dysfunction*
  • Cytokines
  • Endocannabinoids
  • Humans
  • Inflammation
  • Inflammation Mediators
  • Lipoxins* / metabolism
  • Mice

Substances

  • Brain-Derived Neurotrophic Factor
  • Cytokines
  • Endocannabinoids
  • Inflammation Mediators
  • Lipoxins
  • lipoxin A4
  • Arachidonate 5-Lipoxygenase